0.377 -0.004 (-1.05%) | 02-19 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 0.46 ![]() |
1-year : | 0.54 ![]() |
Resists | First : | 0.4 ![]() |
Second : | 0.46 ![]() |
Pivot price | 0.35 ![]() |
|||
Supports | First : | 0.35 ![]() |
Second : | 0.31 |
MAs | MA(5) : | 0.37 ![]() |
MA(20) : | 0.35 ![]() |
MA(100) : | 0.4 ![]() |
MA(250) : | 0.66 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 76.6 ![]() |
D(3) : | 83.4 |
RSI | RSI(14): 53 ![]() |
|||
52-week | High : | 1.74 | Low : | 0.31 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ONVO ] has closed below upper band by 18.3%. Bollinger Bands are 51% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.4 - 0.4 | 0.4 - 0.4 |
Low: | 0.36 - 0.36 | 0.36 - 0.36 |
Close: | 0.37 - 0.38 | 0.38 - 0.38 |
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Wed, 19 Feb 2025
Organovo: Fiscal Q3 Earnings Snapshot - Thehour.com
Wed, 19 Feb 2025
ORGANOVO HOLDINGS, INC. SEC 10-Q Report - TradingView
Mon, 06 Jan 2025
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - The Globe and Mail
Mon, 06 Jan 2025
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - The Manila Times
Mon, 06 Jan 2025
Organovo names new CFO amid clinical advancements - Investing.com
Mon, 06 Jan 2025
Organovo Appoints M&A Veteran CFO as FXR314 Drug Shows Promising Phase 2 Results - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 15 (M) |
Held by Insiders | 1.359e+007 (%) |
Held by Institutions | 2.2 (%) |
Shares Short | 52 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.249e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -8 % |
Return on Assets (ttm) | 693.3 % |
Return on Equity (ttm) | -89.1 % |
Qtrly Rev. Growth | 103000 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -389.99 |
EBITDA (p.s.) | -9.01887e+006 |
Qtrly Earnings Growth | -1.1 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -12 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | 0.83 |
Dividend | 0 |
Forward Dividend | 71890 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |